

Japan lays focus on early detection of heart diseases

06 September 2021 | News

Astellas, Nitto, and M. Heart partnering for ECG testing service



Japanese firms Astellas Pharma Inc., Nitto Denko Corporation, and M. Heart Co., have announced that the three companies have concluded a memorandum of understanding (MoU) concerning an ECG testing service.

Based on this MoU, Astellas, Nitto, and M. Heart will continue to look into Nitto developing and manufacturing the EG Holter a novel disposable holter ECG device, and Astellas exclusively selling it in Japan.

M. Heart will play the role of marketing authorization holder of the EG Holter following from its background of providing development support and regulatory affairs consultations and be responsible for providing the service that will analyze the data obtained from the EG Holter through “MYHOLTER II,” a software for the Holter analyzer (The ECG testing service). In the future, Astellas will aim to provide EG Holter nationwide following pilot-sales.

The EG Holter is disposable and hygienic. It is 6 millimeters thick, 11 grams in weight, has no cords, and is waterproof (IPX4). Patients thus can wear it more comfortably. M. Heart obtained certification for the EG Holter as a medical device (Class II) in August 2021.

By providing a total solution that involves the combining of convenient ECG testing using the EG Holter and the effective and highly accurate data analysis using MYHOLTER II, Astellas, Nitto, and M. Heart are hoping that by promoting early detection and appropriate treatment of atrial fibrillation, a condition estimated to affect approximately 700,000 patients in Japan² they can contribute to the prolongation of healthy life expectancy.